Obstructive Sleep Apnea and Glucose Metabolism
| Status: | Recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies, Endocrine, Pulmonary, Pulmonary |
| Therapuetic Areas: | Endocrinology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 30 - 70 |
| Updated: | 5/5/2018 |
| Start Date: | January 17, 2018 |
| End Date: | February 2023 |
| Contact: | Bettina Mittendorfer, PhD |
| Email: | mittendb@wustl.edu |
| Phone: | 3143628450 |
Many adults who are overweight have obstructive sleep apnea (OSA) which disrupts sleep and
makes it difficult to breath during the night. OSA increases the risk for a person to become
insulin resistant and diabetic. It is not known why OSA causes this problem, i.e., whether it
is disrupted sleep or lack of oxygen., which can change how the body handles glucose in
adipose tissue, muscle tissue and liver.
The purpose of this research study is to determine the key issues and mechanisms responsible
for dysregulated glucose metabolism in people with OSA. The investigators will do this by
comparing glucose metabolism in people who have OSA, and those who do not, and by evaluating
the effect of treating OSA by providing continuous positive airway pressure (CPAP) or simply
oxygen during the night.
The proposed study will evaluate the primary causes(s) (hypoxia, sleep fragmentation, or
both) and pathophysiological mechanisms responsible for the OSA-associated metabolic
abnormalities. Knowing the primary cause of Obstructive Sleep Apnea and pathophysiological
mechanisms responsible for the OSA-associated metabolic abnormalities could help develop
potentially novel therapeutic strategies to provide treatment for adults in improving OSA and
associated comorbidities.
makes it difficult to breath during the night. OSA increases the risk for a person to become
insulin resistant and diabetic. It is not known why OSA causes this problem, i.e., whether it
is disrupted sleep or lack of oxygen., which can change how the body handles glucose in
adipose tissue, muscle tissue and liver.
The purpose of this research study is to determine the key issues and mechanisms responsible
for dysregulated glucose metabolism in people with OSA. The investigators will do this by
comparing glucose metabolism in people who have OSA, and those who do not, and by evaluating
the effect of treating OSA by providing continuous positive airway pressure (CPAP) or simply
oxygen during the night.
The proposed study will evaluate the primary causes(s) (hypoxia, sleep fragmentation, or
both) and pathophysiological mechanisms responsible for the OSA-associated metabolic
abnormalities. Knowing the primary cause of Obstructive Sleep Apnea and pathophysiological
mechanisms responsible for the OSA-associated metabolic abnormalities could help develop
potentially novel therapeutic strategies to provide treatment for adults in improving OSA and
associated comorbidities.
General Inclusion Criteria (for all subjects):
- Age: ≥30 and ≤70 years,
- BMI: ≥30 and ≤45 kg/m2 or body fat ≥ 30 % for women and ≥ 25 % for men,
- Maximum body circumference <170 cm
- Weight stable (≤2% change)
- Untrained (≤1 h of structured exercise/wk) for at least 3 months before entering the
study
- No diabetes (fasting blood glucose <126 mg/dl, 2h oral glucose tolerance test (OGTT)
glucose <200 mg/dl, HbA1c ≤6.5%)
Sleep-related inclusion criteria:
Subjects without OSA:
- AHI <5/h of sleep;
- Oxygen desaturation index <3/h
- No known sleep disorders and periodic limb movement index <15/h during polysomnography
- Reported sleep duration ≥6 h per night
- Regular sleep schedules (i.e. bedtime between 8 pm and 12 am and wake-time between 4
am and 8 am on all days of the week)
Subjects with OSA
- AHI ≥15/h of sleep (i.e., moderate to severe OSA)
- Oxygen desaturation index ≥4/h;
- No polysomnogram finding that would trigger immediate PAP treatment as per standard
operating protocol in our sleep medicine center (a single SaO2 <50%, SaO2 <70% for >2
minutes, electrocardiogram pause >5 sec, or ventricular tachycardia >30 sec), because
of the risk of a potentially adverse outcome if they are not randomized to the PAP
group
- Periodic limb movement index <15/h during polysomnography,
- Reported sleep duration ≥6 h per night,
- Regular night-time sleep schedules, defined as bedtime between 8 pm and 12 am and
wake-time between 4 am and 8 am on all days of the week.
General Exclusion Criteria (for all subjects):
- Current treatment for previously diagnosed OSA;
- Self-reported severe difficulty sleeping in unfamiliar environments;
- Metal implants that are incompatible with magnetic resonance imaging;
- Controlled substances, tobacco products, dietary supplements, or medications known or
suspected to affect sleep, breathing, upper airway muscle physiology, or glucose
metabolism
- Evidence of disease (e.g., diabetes, congestive heart failure; chronic obstructive
pulmonary disease; hypoventilation, defined as daytime partial pressure of carbon
dioxide (pCO2) >45 mm Hg; major neurological or neuromuscular disorders; cancer;
uncontrolled hypertension; etc.);
- Contraindications to supplemental oxygen or PAP (e.g., recent trans-sphenoidal
surgery).
- Unwillingness or inability to provide informed consent
- Study physician considers subject to be unable to safely complete the study protocol
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
